50% of vaccines are wasted - Invention is a disruptive solution to eliminate waste & supply life-saving vaccines to all
United Kingdom, Bath
Problem & Solution
'Every 20 seconds a child dies from a vaccine-preventable disease'
Gates Foundation
Problem: Vaccines are perishable, requiring constant & precise refrigeration from the manufacturer to the patient, be it in a UK Hospital or a clinic in Africa. The WHO estimates that c 50% of all vaccines are wasted in spite of c $400 m p.a. spent on the global Cold Chain
Solution: this patented invention will allow vaccines to be transported & stored for years without refrigeration whilst complying with the protocols set by the WHO. It’s an important breakthrough that can save many lives.
Stablevax comprises approved vaccines which are dried from a solution of stabilising sugar into a special sponge stored in a normal syringe. They are pre-dosed and safe, to use you just add water. Stable vaccines will be manufactured at c. the same price as current products.
StablevaX is the only known product available that achieves vaccine thermostability whilst also complying with the requirements
of the WHO.
Question from Alexis R:
When will you be operational?
Dear Alexis
Thank you for your mail — the simple answer is that revenue starts in c. 36 months — a sit rep of the pathway as follows.
Step 1 — the R&D phase — this has been completed with Proof of Concept (science) achieved.
Step 2 — Our current target milestone will require £750,000 of equity
funding (EIS pre-approved) to achieve the next high value milestone; to GMP manufacture
a StablevaX Tetanus vaccine and submit for clinical trials in Humans on a time line
of c. 12 months leading to regulatory approval.
Step 3 — To obtain regulatory license for the product
and manufacturing, build and operate a pilot scale manufacturing plant
on a timeline of 24 months with funds of c. £ 3.25 M raised
at a higher valuation.
Step 4 — Go to market.
• With Step 3 completed, we will have achieved regulatory approval to market our patented invention for use in Humans.
• We have identified c. 90 approved vaccines that are suitable candidates as future products for the StablevaX process.
• We will establish partnerships for JV’s etc.
• A StablevaX PCV10 vaccine will cost c. $2.50 to produce and sells
across the three price sectors in billions of doses with prices ranging from $3.50 to $180 per dose.
• Full or Part Exit possible during or around this stage.
There are comprehensive details in our Investor and Financial Decks.